Colorectal cancer (CRC) is the second most common type of cancer in Europe and the mortality rate is high, only about half of the patients survive five years after primary diagnosis. CRC develops from benign precursor lesions (adenomas) and invasive colonoscopy remains the best test for early detection of adenomas and carcinomas. However, the development of biomarker based non-invasive screening tests is an area of world-wide interest. Furthermore, the standard treatment protocols for primary and metastatic CRC remain surgery, cytostatics and radiation.
Predisposition to disease
Establishment of non-invasive protocol suitable for population screening to reduce the incidence
Early detection of disease and relapse
Development of new protocols and biomarkers for individual monitoring of early relapse
Establishment of patient stratification beyond today’s clinical staging for more precise individual therapy